A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.
The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.
After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.
Targetmol provides 30 monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.
Cat. No. | 製品名 | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T77748 | Tusamitamab | 2349294-95-5 | 98% |
|
Tusamitamab is an IgG1 monoclonal antibody targeting CEACAM5 and is the naked antibody to Tusamitamab ravtansine.Tusamitamab can be used to synthesize the antibo... | ||||
T77747 | Adecatumumab | 503605-66-1 | 98% |
Adecatumumab
|
Adecatumumab (MT201) is a whole-person IgG1 monoclonal antibody to human EpCAM. Adecatumumab has potential anticancer activity and can be used to study breast ca... | ||||
T9901A-007 | Datopotamab | 2267989-53-5 | 98% |
Datopotamab
|
Datopotamab (CDP7657) is a TROP2-targeting antibody that is a naked antibody to Datopotamab deruxtecan and can be used to synthesize active antibody conjugators ... | ||||
T9901A-005 | Zolbetuximab | 1496553-00-4 | 98% |
|
Zolbetuximab(IMAB362) is a monoclonal antibody that specifically targets Claudin-18.2.Zolbetuximab has potential antitumor activity, mediating killing of Claudin... | ||||
T9901A-004 | Labetuzumab | 219649-07-7 | 98% |
|
Labetuzumab is a humanized anti-carcinoembryonic antigen (CEA) monoclonal antibody with anticancer activity that inhibits tumor growth and is used in the study o... | ||||
T9901A-003 | Gemtuzumab | 2924764-21-4 | 98% |
|
Gemtuzumab(CMA-676) is a monoclonal antibody directed against the CD33 antigen and consists of a recombinant humanized IgG4 antibody.Gemtuzumab can be used to sy... | ||||
T9901A-002 | Enoblituzumab | 1353485-38-7 | 98% |
Enoblituzumab
|
Enoblituzumab is a humanized IgG1 κmab monoclonal antibody that recognizes human B7-H3 protein and can be used to study solid tumors such as non-small cell lung ... | ||||
T9901A-001 | Relatlimab | 1673516-98-7 | 98% |
|
Relatlimab(BMS-986016) is a monoclonal antibody targeting human anti-LAG-3, generated by immunization of transgenic mice with human immunoglobulin carrying recom... | ||||
T9927 | Panitumumab | 339177-26-3 | 98% |
Panitumumab
|
Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR). | ||||
T9929 | Ramucirumab | 947687-13-0 | 98% |
|
Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. | ||||
T9917 | Denosumab | 615258-40-7 | 98% |
Denosumab
|
Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand | ||||
T9926 | Omalizumab | 242138-07-4 |
|
|
Omalizumab is a recombinant humanized monoclonal antibody against human immunoglobulin E IgE) | ||||
T9919 | Alemtuzumab | 216503-57-0 |
Alemtuzumab
|
|
Alemtuzumab is a humanized monoclonal antibody against CD52 an antigen found on the surface of normal and malignant lymphocytes. | ||||
T35394 | Sintilimab (anti-PD-1) | 2072873-06-2 | 95% |
Sintilimab (anti-PD-1)
|
Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding ... | ||||
T38105 | Ixekizumab | 1143503-69-8 | 95.00% |
|
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM.Ixekizumab bloc... | ||||
T76830 | Teneliximab | 299423-37-3 | 95.00% |
Teneliximab
|
Teneliximab (Chi220) is a chimeric monoclonal antibody and a tumor necrosis factor receptor superfamily member 5 (CD40) inhibitor that blocks CD40-CD40L interact... | ||||
T76792 | Sibrotuzumab | 216669-97-5 | 95.00% |
Sibrotuzumab
|
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targeting Fibroblast Activating Protein (FAP).Sibrotuzumab is used in the study of colorectal cance... | ||||
T13666 | Dupilumab | 1190264-60-8 | 95.00% |
|
Dupilumab (REGN-668) is a systemic immunomodulator for AD. Dupilumab is a fully human monoclonal antibody against the alpha subunit of the interleukin-4 receptor... | ||||
T9902 | Atezolizumab | 1380723-44-3 | 95.10% |
|
Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD... | ||||
T76795 | Xentuzumab | 1417158-65-6 | 95.21% |
|
Xentuzumab (BI836845) is a recombinant monoclonal antibody to humanised IGF ligand that inhibits IGF1 and IGF2 growth-promoting signalling and inhibits AKT activ... |